The Accelerated Access Review: final report, commissioned by the government and led by an independent chair, was published on 24th October. The review aims to make the UK a world-leader in healthcare innovation, with an NHS that embraces the new drugs and technologies that patients need and supports work with local areas to develop solutions to their specific healthcare needs.
27 October, 2016
25th October 2016 – Oxford BioDynamics, an Oxford UK-based biotechnology firm, presented at The Lancet Neurology Conference at the Park Plaza Riverbank in London on 20th October 2016. The aim of the conference was to broadcast cutting-edge findings on preclinical neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and Huntington’s disease.
26 October, 2016
New understanding of how cytomegalovirus interacts with host cells provides potential therapeutic target
25 October, 2016
SYNCONA LLP and CANCER RESEARCH TECHNOLOGY (CRT) announce the formation of Achilles Therapeutics Ltd today The new private company will bring together world-class research from UCL (University College London) and the Francis Crick Institute, funded by Cancer Research UK and the National Institute for Health Research (NIHR).
07 October, 2016
The Royal Society of Chemistry (RSC) is returning to Lab Innovations 2016, the UK’s only event dedicated to laboratory professionals, to host a two-day conference in its own dedicated theatre. The hotly anticipated conference programme, taking place at the NEC Birmingham on 2 & 3 November, will feature leading speakers from the laboratory industry who will take to the stage to discuss a series of key topics, including digital healthcare and elemental discovery.
07 October, 2016
Researchers at the University of Bradford have discovered a way to prevent chemotherapy resistance in lung cancer by blocking a protein found in cancer cells.Suppressing this protein, called Ran-GTP, also causes cancer cells already resistant to the first-line chemotherapy treatment, gefitinib, to become re-sensitised to the drug.
06 October, 2016